Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck/Schering Ezetimibe Deal Is Part Of Growing Ties Between Firms

Executive Summary

Merck is edging away from its strict go-it-alone policy and sidling up a little closer to Schering-Plough in a series of deals - the most recent of which is a co-promotion agreement with Schering-Plough for the Phase III cholesterol absorption inhibitor ezetimibe.

You may also be interested in...



Joint Venture On The Rocks? Schering Looks To Compete With Partner Merck

Schering-Plough is exploring opportunities to add Zetia (ezetimibe) to an agent that would give the treatment an entrance into the growing HDL-cholesterol category

Joint Venture On The Rocks? Schering Looks To Compete With Partner Merck

Schering-Plough is exploring opportunities to add Zetia (ezetimibe) to an agent that would give the treatment an entrance into the growing HDL-cholesterol category

Merck Adds To Phase III Pipeline With Lundbeck Sleep-Aid Gaboxadol

Merck's $270 mil. licensing deal for Lundbeck's Phase III sleep disorder agent gaboxadol could give Merck a fifth new product approval around the time that Zocor comes off patent

Related Content

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel